Overview

Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis

Status:
Completed
Trial end date:
2019-12-12
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis.
Phase:
Phase 2
Details
Lead Sponsor:
Insmed Incorporated